Pamela B Allen1, Barbara Pro2. 1. Winship Institute of Emory University, 1365 Clifton Rd NE, Suite 4400, Atlanta, GA, USA. 2. Department of Medicine, Division of Hematology/Oncology, Northwestern University Feinberg School of Medicine, Robert H. Lurie Comprehensive Cancer Center, Northwestern University, 676 N. St. Clair Street, Suite 850, Chicago, IL, 60611, USA. Barbara.Pro@nm.org.
Abstract
PURPOSE OF REVIEW: Peripheral T cell lymphomas (PTCLs) are a heterogeneous group of non-Hodgkin lymphomas with inferior prognosis compared with their B cell counterparts characterized by frequent relapses, resulting in a median 5-year survival of approximately 30%. Their diverse clinicopathologic features challenge existing treatment paradigms that treat all patients uniformly. Here we review recent advances in the treatment of these diseases. RECENT FINDINGS: While current treatment still relies largely on combination chemotherapy, the introduction of more effective novel and targeted therapies has improved outcomes in certain subtypes. Increasing understanding of the underlying biology of PTCL has prompted further subclassification by genetic and molecular subgroups. Overall, the most significant advances in PTCL management have resulted from improved understanding and classification of the biology of PTCL. Ongoing development of subtype-specific targeted therapies will be essential to improve long-term outcomes of patients with these diseases.
PURPOSE OF REVIEW: Peripheral T cell lymphomas (PTCLs) are a heterogeneous group of non-Hodgkin lymphomas with inferior prognosis compared with their B cell counterparts characterized by frequent relapses, resulting in a median 5-year survival of approximately 30%. Their diverse clinicopathologic features challenge existing treatment paradigms that treat all patients uniformly. Here we review recent advances in the treatment of these diseases. RECENT FINDINGS: While current treatment still relies largely on combination chemotherapy, the introduction of more effective novel and targeted therapies has improved outcomes in certain subtypes. Increasing understanding of the underlying biology of PTCL has prompted further subclassification by genetic and molecular subgroups. Overall, the most significant advances in PTCL management have resulted from improved understanding and classification of the biology of PTCL. Ongoing development of subtype-specific targeted therapies will be essential to improve long-term outcomes of patients with these diseases.
Entities:
Keywords:
Anaplastic large-cell lymphoma; Angioimmunoblastic T cell lymphoma; Peripheral T cell lymphoma; Relapsed disease; Therapy
Authors: Javeed Iqbal; Ryan Wilcox; Hina Naushad; Joseph Rohr; Tayla B Heavican; Chao Wang; Alyssa Bouska; Kai Fu; Wing C Chan; Julie M Vose Journal: Blood Rev Date: 2015-08-18 Impact factor: 8.250
Authors: José Rodríguez; Eulogio Conde; Antonio Gutiérrez; Reyes Arranz; Marcos Gandarillas; Angel Leon; Jesus Ojanguren; Anna Sureda; Dolores Carrera; Mauricio Bendandi; Jose Moraleda; Jose Maria Ribera; Carmen Albo; Alfonso Morales; Juan Carlos García; Pascual Fernández; Guillermo Cañigral; Juan Bergua; María Dolores Caballero Journal: Eur J Haematol Date: 2007-04 Impact factor: 2.997
Authors: Matthew J Maurer; Fredrik Ellin; Line Srour; Mats Jerkeman; N Nora Bennani; Joseph M Connors; Graham W Slack; Karin E Smedby; Stephen M Ansell; Brian K Link; James R Cerhan; Thomas Relander; Kerry J Savage; Andrew L Feldman Journal: J Clin Oncol Date: 2017-10-26 Impact factor: 44.544
Authors: S Mercadal; J Briones; B Xicoy; C Pedro; L Escoda; C Estany; M Camós; L Colomo; I Espinosa; S Martínez; J M Ribera; R Martino; G Gutiérrez-García; E Montserrat; A López-Guillermo Journal: Ann Oncol Date: 2008-02-25 Impact factor: 32.976
Authors: J S Abramson; T Feldman; A R Kroll-Desrosiers; L S Muffly; E Winer; C R Flowers; F Lansigan; C Nabhan; L J Nastoupil; R Nath; A Goy; J J Castillo; D Jagadeesh; B Woda; S T Rosen; S M Smith; A M Evens Journal: Ann Oncol Date: 2014-09-05 Impact factor: 32.976
Authors: Monica Bellei; Francine M Foss; Andrei R Shustov; Steven M Horwitz; Luigi Marcheselli; Won Seog Kim; Maria E Cabrera; Ivan Dlouhy; Arnon Nagler; Ranjana H Advani; Emanuela A Pesce; Young-Hyeh Ko; Virginia Martinez; Silvia Montoto; Carlos Chiattone; Alison Moskowitz; Michele Spina; Irene Biasoli; Martina Manni; Massimo Federico Journal: Haematologica Date: 2018-03-29 Impact factor: 9.941
Authors: Francesco Maura; Anna Dodero; Cristiana Carniti; Niccolò Bolli; Martina Magni; Valentina Monti; Antonello Cabras; Daniel Leongamornlert; Federico Abascal; Benjamin Diamond; Bernardo Rodriguez-Martin; Jorge Zamora; Adam Butler; Inigo Martincorena; Jose M C Tubio; Peter J Campbell; Annalisa Chiappella; Giancarlo Pruneri; Paolo Corradini Journal: Haematologica Date: 2021-11-01 Impact factor: 9.941